ATE445644T1 - Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten - Google Patents

Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten

Info

Publication number
ATE445644T1
ATE445644T1 AT06728255T AT06728255T ATE445644T1 AT E445644 T1 ATE445644 T1 AT E445644T1 AT 06728255 T AT06728255 T AT 06728255T AT 06728255 T AT06728255 T AT 06728255T AT E445644 T1 ATE445644 T1 AT E445644T1
Authority
AT
Austria
Prior art keywords
mcp
molecules
treat
methods
application
Prior art date
Application number
AT06728255T
Other languages
English (en)
Inventor
Nathan Karin
Gizi Wildbaum
Yaniv Zohar
Liat Izhak
Uri Weinberg
Original Assignee
Rappaport Family Inst For Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rappaport Family Inst For Res filed Critical Rappaport Family Inst For Res
Application granted granted Critical
Publication of ATE445644T1 publication Critical patent/ATE445644T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06728255T 2005-04-15 2006-04-10 Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten ATE445644T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67147605P 2005-04-15 2005-04-15
PCT/IL2006/000454 WO2006109301A2 (en) 2005-04-15 2006-04-10 Molecules and methods of using same for treating mcp-1/ccr2 associated diseases

Publications (1)

Publication Number Publication Date
ATE445644T1 true ATE445644T1 (de) 2009-10-15

Family

ID=36688002

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06728255T ATE445644T1 (de) 2005-04-15 2006-04-10 Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten

Country Status (11)

Country Link
US (1) US8388962B2 (de)
EP (1) EP1871798B1 (de)
JP (1) JP2008535909A (de)
CN (1) CN101160323A (de)
AT (1) ATE445644T1 (de)
AU (1) AU2006233927A1 (de)
CA (1) CA2597789A1 (de)
DE (1) DE602006009786D1 (de)
ES (1) ES2333358T3 (de)
MX (1) MX2007010484A (de)
WO (1) WO2006109301A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535909A (ja) 2005-04-15 2008-09-04 ラパポート ファミリー インスティテュート フォー リサーチ イン ザ メディカル サイエンシーズ Ｍｃｐ−１／ｃｃｒ２関連疾患を治療するための分子およびその使用方法
US20080118437A1 (en) * 2006-03-01 2008-05-22 Regents Of The University Of Michigan Diagnosis and treatment O prostate cancer
EP2193805A4 (de) 2007-08-24 2013-09-04 Univ Keio Immunsuppressions-entwöhnungsmittel mit tumorzellen und dieses verwendende antitumorale mittel
CN102370981B (zh) * 2010-08-11 2014-07-16 中国科学院上海生命科学研究院 防治神经退行性疾病的试剂和方法
US20160184347A1 (en) * 2013-08-06 2016-06-30 Kyushu University, National University Corporation Medicine for preventing or suppressing engraftment of cancer cells including an organic acid polymer as active ingredient
NO2776305T3 (de) 2014-04-23 2018-01-27
CN107362353A (zh) * 2016-05-11 2017-11-21 上海长海医院 一种去势抵抗的前列腺癌相关的药物靶点及其应用
KR102308102B1 (ko) * 2018-05-18 2021-10-07 가톨릭대학교 산학협력단 Ccr2를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물
WO2021095946A1 (ko) * 2019-11-15 2021-05-20 가톨릭대학교 산학협력단 Ccr2를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물
KR102308099B1 (ko) * 2019-11-15 2021-10-01 가톨릭대학교 산학협력단 Soluble CCR2 발현 유도된 줄기세포를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3532570B2 (ja) * 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
WO2001058916A2 (en) 2000-02-09 2001-08-16 Human Genome Sciences, Inc. Antibodies to ccr5
FR2828102B1 (fr) * 2001-03-28 2004-07-09 Ifc Sa Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
CA2531526C (en) 2003-07-24 2012-08-21 Amgen Inc. Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor
IL157398A0 (en) 2003-08-14 2004-02-19 Hadasit Med Res Service Pharmaceutical compositions comprising ccr5 antagonists
US7943130B2 (en) 2003-12-11 2011-05-17 Yale University Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation
US20050215543A1 (en) 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
JP2008535909A (ja) 2005-04-15 2008-09-04 ラパポート ファミリー インスティテュート フォー リサーチ イン ザ メディカル サイエンシーズ Ｍｃｐ−１／ｃｃｒ２関連疾患を治療するための分子およびその使用方法

Also Published As

Publication number Publication date
CA2597789A1 (en) 2006-10-19
AU2006233927A1 (en) 2006-10-19
US8388962B2 (en) 2013-03-05
CN101160323A (zh) 2008-04-09
WO2006109301A2 (en) 2006-10-19
ES2333358T3 (es) 2010-02-19
DE602006009786D1 (de) 2009-11-26
EP1871798A2 (de) 2008-01-02
MX2007010484A (es) 2007-10-15
EP1871798B1 (de) 2009-10-14
US20110033521A1 (en) 2011-02-10
WO2006109301A3 (en) 2006-12-07
JP2008535909A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
ATE445644T1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE464323T1 (de) Zusammensetzungen und verfahren für die tumor- diagnose und behandlung
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE545418T1 (de) Zusammensetzungen und kits zur behandlung von influenza
EA200802054A1 (ru) Ингибиторы фермента
ATE500855T1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
NO20092637L (no) Fremgangsmater for behandling
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
EA201070247A1 (ru) Ингибиторы протеасом
NO20065297L (no) Anvendelse av GPCR54 ligander til behandling av infertilitet
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
DE60335636D1 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties